semagacestat

  1. T

    Lilly Halts Dosing In Phase III Alzheimer's Disease Drug Trial Of Semagacestat

    All or excerpts from the following statement can be attributed to William Thies, Ph.D., Alzheimer's Association Chief Medical and Scientific Officer: The Alzheimer's Association is disappointed to learn of the negative interim results from the Phase III clinical trial of Semagacestat. People...
Back
Top